Gapping up
In reaction to strong earnings/guidance:
- MANH +7.1%, TER +6.2%, BSX +4.8%, OC +4%, TMO +4%, ABB +3.6%, HCSG +3.4%, CLF +3.4%, USNA +3.3%, ALXN +3.2%, TDY +2.6%, CSTM +2.4%, CSL +2%, FMBI +1.8%, ROL +1.8%, ANTM +1.6%, VNE +1.5%, BA +1.5%, SLAB +1.4%, SNAP +1.3%, LAD +1.3%, NAVI +1.2%, DFS +1%, NTB +0.7%, NDAQ +0.7%, LPL +0.6%, CAT +0.5%
Other news:
- HNGR +10% (to join S&P SmallCap 600, effective prior to the open on October 28)
- MRNA +4.2% (Moderna receives FDA Fast Track designation for mRNA-3927)
- BIIB +2% (continued strength; also updates on legal matters in 10-Q, has participated in preliminary discussions with the government regarding potential resolution of aspects of inquiry into the company's relationship with non-profit organizations)
- AXGT +1.3% (announces preliminary data from an expanded access study administering investigational AXO-AAV-GM2 gene therapy in two patients with infantile Tay-Sachs disease)
- HAS +1% (following yesterday's sharp earnings related decline; CEO interviewed on CNBC MadMoney after the close)
Analyst comments:
- SENS +4.6% (initiated with a Buy at Stifel)
- TNK +2% (upgraded to Buy from Hold at Jefferies)
- SNAP +1.3% (upgraded to Overweight from Neutral at JP Morgan)
- CRWD +0.9% (initiated with a Buy at Nomura)
- KO +0.5% (upgraded to Buy from Neutral at UBS)